Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 372,452 shares of the biopharmaceutical company’s stock after purchasing an additional 42,554 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Gilead Sciences were worth $30,172,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in GILD. Robertson Stephens Wealth Management LLC raised its stake in Gilead Sciences by 32.4% during the 4th quarter. Robertson Stephens Wealth Management LLC now owns 5,349 shares of the biopharmaceutical company’s stock worth $433,000 after acquiring an additional 1,310 shares in the last quarter. McIlrath & Eck LLC grew its holdings in shares of Gilead Sciences by 67.2% during the fourth quarter. McIlrath & Eck LLC now owns 550 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 221 shares during the last quarter. First Trust Direct Indexing L.P. increased its position in shares of Gilead Sciences by 23.0% during the fourth quarter. First Trust Direct Indexing L.P. now owns 30,157 shares of the biopharmaceutical company’s stock worth $2,443,000 after purchasing an additional 5,648 shares in the last quarter. Searle & CO. purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at about $328,000. Finally, Concord Wealth Partners boosted its position in shares of Gilead Sciences by 34.3% in the 4th quarter. Concord Wealth Partners now owns 18,355 shares of the biopharmaceutical company’s stock valued at $1,487,000 after purchasing an additional 4,684 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Maxim Group reduced their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday. Wells Fargo & Company reduced their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. Oppenheimer reissued an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research report on Friday, April 19th. Morgan Stanley reduced their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Finally, Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price target for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $64.78 on Friday. The company has a market cap of $80.66 billion, a P/E ratio of 179.94, a price-to-earnings-growth ratio of 1.30 and a beta of 0.22. Gilead Sciences, Inc. has a one year low of $64.33 and a one year high of $87.86. The business has a fifty day moving average of $70.55 and a two-hundred day moving average of $75.83. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter last year, the business earned $1.37 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, analysts predict that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.75%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.